GO:0070568 guanylyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070568 (guanylyltransferase activity) is a molecular function defined as the catalysis of guanylyl group transfer to an acceptor.
• Guanylyltransferases are essential for mRNA capping, where they transfer GMP to the 5' diphosphate end of nascent RNA.
• Viral guanylyltransferases, such as vaccinia capping enzyme and rotavirus VP3, are validated drug targets and model enzymes.
• Human Thg1 (THG1L) is a tRNA guanylyltransferase that adds a guanylate to the 5' end of tRNA-His and displays tRNA-inducible GTPase activity.
• Bacterial guanylyltransferases like CobU from Akkermansia muciniphila are involved in cobalamin biosynthesis and are structurally distinct from eukaryotic enzymes.
• Studying guanylyltransferase activity requires combining biochemical assays, structural biology, and CRISPR-based genetic models.
Description
Guanylyltransferase activity (GO:0070568) is a fundamental enzymatic function that transfers a guanylyl group from a donor molecule, typically GTP, to an acceptor substrate. This activity is best known for its role in mRNA capping, where it adds a guanosine monophosphate (GMP) cap to the 5' end of nascent RNA transcripts, a modification critical for RNA stability, splicing, and translation. The enzyme was first purified and characterized from vaccinia virus, where the guanylyltransferase activity is part of a multifunctional capping enzyme complex. Since then, guanylyltransferases have been identified across all domains of life, including viruses, bacteria, and eukaryotes. In eukaryotes, the capping enzyme guanylyltransferase is essential for gene expression, while in bacteria, enzymes like CobU catalyze guanylyl transfer in coenzyme B12 biosynthesis. The diversity of guanylyltransferases underscores their broad biological importance and their potential as targets for antiviral and antibacterial therapies. Researchers study this activity to understand RNA processing, viral replication, and metabolic pathways, and to develop inhibitors that block these processes.
guanylyltransferase activity At A Glance
| GO ID | GO:0070568 |
|---|---|
| GO term | guanylyltransferase activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Catalysis of the transfer of a guanylyl group to an acceptor. |
| Major function | RNA capping, tRNA modification, cobalamin biosynthesis |
| EC number | 2.7.7.50 (mRNA guanylyltransferase) |
| Representative enzymes | Vaccinia capping enzyme, rotavirus VP3, human Thg1, bacterial CobU |
| Cofactors | Divalent cations (e.g., Mg2+) may be required for some enzymes |
What Is GO:0070568?
Guanylyltransferase activity (GO:0070568) is defined by the Gene Ontology as the catalysis of the transfer of a guanylyl group to an acceptor molecule. In practice, this typically involves the transfer of GMP from GTP to a 5' diphosphate terminus of RNA, forming a 5'-5' triphosphate linkage (the cap structure). The reaction releases pyrophosphate and is often coupled with RNA triphosphatase and methyltransferase activities in a capping enzyme complex. The acceptor can also be a protein or a small molecule, as seen in bacterial cobalamin biosynthesis where CobU transfers GMP to adenosylcobinamide-phosphate.
Why Is guanylyltransferase activity Important in Cell Biology?
Guanylyltransferase activity is essential for mRNA capping, a process that protects RNA from degradation, facilitates nuclear export, and enhances translation. In viruses, guanylyltransferases are critical for replication and immune evasion, making them attractive antiviral targets. In humans, the tRNA guanylyltransferase Thg1 (THG1L) is involved in tRNA quality control and has been linked to neurological disorders. Bacterial guanylyltransferases like CobU are required for cobalamin synthesis, and their inhibition could disrupt bacterial metabolism. Thus, understanding guanylyltransferase activity has broad implications for basic biology, medicine, and biotechnology.
• mRNA capping: guanylyltransferases add the 5' cap, essential for RNA stability and translation.
• Viral replication: many viruses encode guanylyltransferases for capping their RNA, a target for antivirals.
• tRNA modification: human Thg1 adds a guanylate to tRNA-His, critical for tRNA maturation.
• Cobalamin biosynthesis: bacterial CobU catalyzes guanylyl transfer in vitamin B12 production.
• Disease association: mutations in THG1L cause spinocerebellar ataxia and other neurological phenotypes.
• Biotechnology: capping enzymes are used in mRNA vaccine production.
• Structural biology: guanylyltransferases provide models for enzyme mechanism and drug design.
• Evolution: guanylyltransferases are found in all domains of life, revealing conserved and divergent mechanisms.
What Happens During guanylyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs GTP and the acceptor molecule, such as the end of an RNA strand.
Guanylyltransferases bind GTP and the acceptor substrate, which is typically the 5' diphosphate end of RNA or a small molecule like adenosylcobinamide-phosphate. In the vaccinia capping enzyme, the guanylyltransferase domain recognizes the diphosphate terminus of nascent RNA and positions it for attack. For human Thg1, the acceptor is the 5' end of tRNA-His, and binding is tRNA-inducible, triggering a conformational change that activates the enzyme.
Formation of enzyme-GMP intermediate
In simple terms: The enzyme temporarily holds onto GMP, releasing pyrophosphate.
The catalytic mechanism involves the formation of a covalent enzyme-GMP intermediate. In vaccinia guanylyltransferase, a conserved lysine residue attacks GTP, releasing pyrophosphate and forming a phosphoamide bond with GMP. This intermediate is then transferred to the RNA acceptor. Rotavirus VP3 also forms a covalent intermediate, as shown by biochemical assays. The formation of this intermediate is a key step that can be targeted by inhibitors.
Guanylyl transfer to acceptor
In simple terms: GMP is attached to the RNA or other acceptor, creating the cap.
The GMP moiety is transferred from the enzyme to the 5' diphosphate end of the acceptor RNA, forming a 5'-5' triphosphate linkage (the cap). This reaction is essential for mRNA stability and translation. In rat liver nuclei, the guanylyltransferase associates with RNA 5'-triphosphatase, which first converts the 5' triphosphate to a diphosphate, the preferred substrate for guanylyl transfer. In bacteria, CobU transfers GMP to adenosylcobinamide-phosphate, forming adenosylcobinamide-GDP, a precursor in cobalamin biosynthesis.
Release of capped product and enzyme recycling
In simple terms: The capped RNA is released, and the enzyme is ready for another round.
After transfer, the capped RNA or product is released, and the enzyme returns to its initial state to catalyze another reaction. In the vaccinia capping enzyme complex, the guanylyltransferase works with methyltransferase to complete cap formation. The enzyme's activity can be regulated by post-translational modifications; for example, glutathionylation of the NS5 capping domain from dengue, Japanese encephalitis, and Zika viruses modulates guanylyltransferase activity. This regulation may affect viral replication efficiency.
Key Genes Involved in GO:0070568 guanylyltransferase activity
The following genes and proteins are representative of guanylyltransferase activity across viruses, bacteria, and eukaryotes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Vaccinia virus D1R | mRNA capping enzyme guanylyltransferase | Model for capping mechanism and antiviral target |
| Vaccinia virus D12L | Methyltransferase subunit of capping enzyme | Part of heterodimeric capping enzyme complex |
| Rotavirus VP3 | Guanylyltransferase and methyltransferase | Essential for viral RNA capping; antiviral target |
| Baculovirus LEF-4 | RNA polymerase subunit with guanylyltransferase | Required for viral transcription |
| Human THG1L | tRNA-His guanylyltransferase | tRNA maturation and neurological disease |
| Akkermansia muciniphila CobU | Adenosylcobinamide-phosphate guanylyltransferase | Cobalamin biosynthesis; antibacterial target |
| Dengue virus NS5 | N-terminal capping domain with guanylyltransferase | Glutathionylation regulates activity |
| Zika virus NS5 | N-terminal capping domain with guanylyltransferase | Glutathionylation regulates activity |
| Japanese encephalitis virus NS5 | N-terminal capping domain with guanylyltransferase | Glutathionylation regulates activity |
| Rat liver RNA guanylyltransferase | mRNA capping in nuclei | Associated with RNA 5'-triphosphatase |
| Saccharomyces cerevisiae Ceg1 | mRNA guanylyltransferase | Model for eukaryotic capping |
| Human RNGTT | mRNA guanylyltransferase | Essential for mRNA capping in humans |
| Escherichia coli CobU | Guanylyltransferase in cobalamin synthesis | Bacterial model for enzyme mechanism |
| Vaccinia virus J3R | Methyltransferase in capping enzyme | Part of capping complex |
| Baculovirus VP39 | Methyltransferase | Associated with LEF-4 |
| Human THG1 | tRNA guanylyltransferase | GTPase activity and tRNA editing |
| Akkermansia muciniphila CobU homolog | Guanylyltransferase | Structural insights into bacterial enzyme |
How Is guanylyltransferase activity Regulated?
Guanylyltransferase activity is regulated at multiple levels. Viral enzymes can be modulated by post-translational modifications such as glutathionylation, which affects the capping activity of dengue, Zika, and Japanese encephalitis virus NS5 proteins. In human cells, Thg1 activity is tRNA-inducible, meaning it requires the presence of tRNA-His for activation, and it also exhibits GTPase activity that may regulate its function. The vaccinia capping enzyme is part of a complex with methyltransferase, and its activity is coordinated with RNA triphosphatase to ensure efficient cap formation. Additionally, the expression levels of guanylyltransferases can be regulated transcriptionally, although specific transcription factors are not well defined for all family members.
guanylyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| THG1L | Spinocerebellar ataxia, neurological disorders | Knockout or point-mutation in human cell lines; neuronal differentiation models |
| Vaccinia virus D1R | Viral replication, antiviral target | Infection models with knockout virus; drug screening |
| Rotavirus VP3 | Gastroenteritis, antiviral target | Rotavirus infection in cell culture; VP3 inhibitors |
| Dengue/Zika NS5 | Flavivirus infection, redox regulation | Glutathionylation mutants; antiviral assays |
| Akkermansia muciniphila CobU | Cobalamin biosynthesis, bacterial metabolism | Bacterial knockout; structural studies |
Viral infections and antiviral targets
Many viruses rely on guanylyltransferases for capping their mRNA, which is essential for viral replication and immune evasion. Vaccinia virus, rotavirus, and baculovirus encode guanylyltransferases that are critical for their life cycles. Inhibiting these enzymes blocks viral replication, making them attractive antiviral targets. For example, the vaccinia capping enzyme is a model for developing broad-spectrum antivirals. Dengue, Zika, and Japanese encephalitis viruses also encode guanylyltransferases in their NS5 protein, and their activity is regulated by glutathionylation, suggesting a link to cellular redox state.
Neurological disorders associated with THG1L mutations
Human THG1L encodes a tRNA guanylyltransferase that adds a guanylate to the 5' end of tRNA-His, a critical step in tRNA maturation. Mutations in THG1L have been linked to spinocerebellar ataxia and other neurological phenotypes, although the exact mechanisms are still under investigation. The enzyme's tRNA-inducible GTPase activity suggests a role in tRNA quality control, and its dysfunction may lead to accumulation of misfolded tRNAs and neuronal stress.
Bacterial metabolism and cobalamin biosynthesis
Bacterial guanylyltransferases such as CobU from Akkermansia muciniphila are involved in the biosynthesis of cobalamin (vitamin B12). CobU catalyzes the transfer of GMP to adenosylcobinamide-phosphate, a key step in the pathway. Structural studies have revealed unique features of this enzyme that could be exploited for antibacterial drug design. Disruption of cobalamin biosynthesis affects bacterial metabolism and may influence host-microbe interactions.
From guanylyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of THG1L loss on tRNA modification? | THG1L knockout in HEK293 or neuronal cells |
| How does glutathionylation regulate flavivirus guanylyltransferase? | Point mutations of cysteine residues in NS5; glutathionylation assays |
| Can we develop inhibitors of viral capping enzymes? | Overexpression of vaccinia or rotavirus guanylyltransferase; high-throughput screening |
| What is the role of CobU in cobalamin biosynthesis? | CobU knockout in Akkermansia muciniphila; metabolomics |
| How does LEF-4 contribute to baculovirus transcription? | LEF-4 knockout baculovirus; RNA polymerase assays |
| Does human RNGTT have non-canonical functions? | Knock-in of tagged RNGTT; proteomics |
How to Study the guanylyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTP-pyrophosphate exchange assay | Covalent enzyme-GMP intermediate formation | Purification and kinetic analysis |
| Radiolabeled GMP transfer assay | Guanylyl transfer to RNA acceptor | Activity measurement |
| X-ray crystallography | Three-dimensional structure of enzyme-substrate complex | Mechanistic insights and drug design |
| CRISPR knockout | Loss-of-function phenotype | Gene function in cells |
| RNA-seq | Transcriptome changes | Identifying pathways affected by guanylyltransferase loss |
| Proteomics | Protein expression and modifications | Detecting glutathionylation |
| In vitro capping assay | Cap formation on synthetic RNA | Viral enzyme characterization |
| High-throughput screening | Inhibitor identification | Antiviral drug discovery |
Biochemical assays for guanylyltransferase activity
Guanylyltransferase activity is typically measured using a GTP-pyrophosphate exchange assay, which detects the formation of a covalent enzyme-GMP intermediate. This assay was used to purify the vaccinia capping enzyme and to characterize rotavirus VP3. Alternatively, the transfer of radiolabeled GMP from GTP to an RNA acceptor can be monitored by gel electrophoresis or thin-layer chromatography. These methods are essential for kinetic characterization and inhibitor screening.
Structural biology approaches
X-ray crystallography and cryo-electron microscopy have provided insights into the catalytic mechanism of guanylyltransferases. The structure of CobU from Akkermansia muciniphila revealed the active site and substrate binding residues. Structures of the vaccinia capping enzyme in complex with GTP and RNA have elucidated the two-step mechanism involving a covalent intermediate. These structural studies guide the design of specific inhibitors.
Genetic and CRISPR-based methods
CRISPR-Cas9 knockout of guanylyltransferase genes in human cells or bacteria can reveal their cellular functions. For example, THG1L knockout in human cells affects tRNA maturation and cell viability. Knockout of CobU in Akkermansia muciniphila disrupts cobalamin biosynthesis. Overexpression of viral guanylyltransferases in mammalian cells can be used to study their effects on RNA capping and immune responses.
Omics and bioinformatics
RNA sequencing (RNA-seq) can identify changes in gene expression upon guanylyltransferase inhibition or knockout. For instance, knocking out THG1L may alter tRNA levels and stress response pathways. Proteomics can detect post-translational modifications like glutathionylation on viral guanylyltransferases. Bioinformatics tools can predict guanylyltransferase domains and guide functional studies.
How CRISPR Can Be Used to Study GO:0070568 guanylyltransferase activity
Knockout
CRISPR-Cas9 knockout of guanylyltransferase genes such as THG1L or CobU can reveal their essential roles. For example, THG1L knockout in human cells leads to tRNA maturation defects and may affect cell proliferation. In bacteria, CobU knockout disrupts cobalamin biosynthesis, which can be assessed by metabolomics. Knockout of viral guanylyltransferases using CRISPR is challenging due to viral genomes, but can be achieved with CRISPR interference or by targeting host factors.
Point Mutation
Point mutations in catalytic residues of guanylyltransferases can abolish activity and help map functional domains. For instance, mutating the active-site lysine in vaccinia guanylyltransferase prevents covalent intermediate formation. Similarly, mutating cysteine residues in dengue NS5 affects glutathionylation and enzyme activity. These mutants are valuable for dissecting mechanism and for validating drug targets.
Knock-in
Knock-in of tagged guanylyltransferases (e.g., FLAG or GFP) allows for localization and interaction studies. A tagged THG1L knock-in can be used to immunoprecipitate tRNA complexes and identify binding partners. Knock-in of viral guanylyltransferases into host cells can facilitate live-cell imaging of capping enzyme dynamics.
Overexpression
Overexpression of guanylyltransferases in mammalian or bacterial cells can produce large amounts of enzyme for biochemical and structural studies. For example, recombinant vaccinia capping enzyme is overexpressed for crystallization. Overexpression of dengue NS5 in cells can be used to study its effects on RNA capping and innate immune evasion. This approach is also useful for screening inhibitors.
How EDITGENE Supports guanylyltransferase activity Research
Researchers studying guanylyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in RNA processing, viral replication, or metabolic pathways. EDITGENE provides comprehensive CRISPR-based services to generate precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for guanylyltransferase activity research.
Frequently Asked Questions About guanylyltransferase activity
What is guanylyltransferase activity?
Guanylyltransferase activity (GO:0070568) is the catalysis of the transfer of a guanylyl group to an acceptor molecule, commonly forming the 5' cap of mRNA.
What genes are involved in guanylyltransferase activity?
Key genes include vaccinia virus D1R, rotavirus VP3, human THG1L and RNGTT, and bacterial CobU.
What is the role of guanylyltransferase in mRNA capping?
It adds a GMP cap to the 5' end of nascent RNA, which protects the RNA and facilitates translation.
How is guanylyltransferase activity regulated?
It can be regulated by post-translational modifications like glutathionylation and by substrate availability, such as tRNA for THG1L.
What diseases are associated with guanylyltransferase mutations?
Mutations in THG1L are linked to neurological disorders, and viral guanylyltransferases are targets for antiviral therapy.
What methods are used to study guanylyltransferase activity?
Common methods include GTP-pyrophosphate exchange assays, radiolabeled GMP transfer, X-ray crystallography, and CRISPR knockout models.
Can CRISPR be used to study guanylyltransferase genes?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect gene function and regulation.
What is the difference between guanylyltransferase and methyltransferase?
Guanylyltransferase adds GMP to form the cap, while methyltransferase adds methyl groups to the cap structure; they often work together in capping enzymes.
Is guanylyltransferase activity found in bacteria?
Yes, bacterial enzymes like CobU catalyze guanylyl transfer in cobalamin biosynthesis.
How can I inhibit guanylyltransferase activity?
Inhibitors can target the covalent enzyme-GMP intermediate or substrate binding; high-throughput screening is used to identify such compounds.
Conclusion
Guanylyltransferase activity (GO:0070568) is a versatile enzymatic function essential for RNA capping, tRNA modification, and bacterial metabolism. Its roles in viral replication and human disease make it a compelling target for therapeutic development. Advances in structural biology and CRISPR-based genetics continue to illuminate its mechanisms and regulation. EDITGENE's suite of CRISPR services empowers researchers to create precise models for studying guanylyltransferase biology and to accelerate drug discovery.
References
- 1. Saisawang C et al.. 2023. Effects of Glutathionylation on Guanylyltransferase Activity of NS5 N-terminal Capping Domain from Dengue, Japanese Encephalitis, and Zika Viruses.. Protein Pept Lett 30(5):439-447 PMID: 37076471
- 2. Jiang M et al.. 2025. Structural insights into the adenosylcobinamide-phosphate guanylyltransferase activity of CobU from Akkermansia muciniphila.. Int J Biol Macromol 329(Pt 1):147810 PMID: 40976292
- 4. Antika TR et al.. 2022. Human Thg1 displays tRNA-inducible GTPase activity.. Nucleic Acids Res 50(17):10015-10025 PMID: 36107775
- 5. Shuman S et al.. 1980. Purification and characterization of a GTP-pyrophosphate exchange activity from vaccinia virions. Association of the GTP-pyrophosphate exchange activity with vaccinia mRNA guanylyltransferase . RNA (guanine-7-)methyltransferase complex (capping enzyme).. J Biol Chem 255(23):11588-98 PMID: 6254974
- 6. Yagi Y et al.. 1983. Association of an RNA 5'-triphosphatase activity with RNA guanylyltransferase partially purified from rat liver nuclei.. EMBO J 2(4):611-5 PMID: 6138253
- 7. Pizarro JL et al.. 1991. Characterization of rotavirus guanylyltransferase activity associated with polypeptide VP3.. J Gen Virol 72 ( Pt 2):325-32 PMID: 1704411
- 8. Guarino LA et al.. 1998. Guanylyltransferase activity of the LEF-4 subunit of baculovirus RNA polymerase.. J Virol 72(12):10003-10 PMID: 9811738
